Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3 clinical trials
Tagraxofusp (SL-401) in Patients With CMML or MF

(MF). There are two CMML cohorts, one enrolling patients with CMML (CMML-1 or CMML-2) who are refractory/resistant or intolerant to hypomethylating agents (HMA), hydroxyurea (HU), or intensive

myelomonocytic leukemia
myelofibrosis
anemia
monocytosis
leukemia
  • 145 views
  • 10 May, 2022
  • 10 locations
Combining Active and Passive DNA Hypomethylation

patients with higher-risk MDS, CMML-2 or low-blast count AML. The primary purpose is to investigate if oral vitamin C supplementation to azacitidine, compared with azacitidine + placebo, can increase the

cancer
azacitidine
blast cells
stem cell transplantation
cell transplantation
  • 0 views
  • 08 Oct, 2021
  • 6 locations
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Seclidemstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine may help block the formation of …

myelomonocytic leukemia
cancer
azacitidine
leukemia
TP53
  • 0 views
  • 25 Mar, 2022
  • 1 location